United States · FDA National Drug Code directory
Doxorubicin Hydrochloride Liposome
A source-listed medicine record.
Factual source checks only. This page is not a clinically reviewed monograph. Historical or discontinued records may be included; listing does not confirm approval, current availability or pharmacy stock.
Medicine identity
- Source reference
- 25021-263_97cdef7c-93c7-4c7a-9a51-fc260a6a4521
- Product NDC
- 25021-263
- Form
- INJECTION, SUSPENSION, LIPOSOMAL
- Composition / generic term
- Doxorubicin Hydrochloride
- Labeler
- Sagent Pharmaceuticals
- Marketing category
- ANDA
- Marketing start / end (source format)
- 20260301
- Source listing expiry
- 20271231
Source-listed ingredients
- DOXORUBICIN HYDROCHLORIDE — 2 mg/mL
These values do not establish equivalence or a dose recommendation.
Packages
- 1 VIAL in 1 CARTON (25021-263-10) / 10 mL in 1 VIAL · 25021-263-10
- 1 VIAL in 1 CARTON (25021-263-25) / 25 mL in 1 VIAL · 25021-263-25
Source and coverage
Open FDA National Drug Code directory →
Snapshot retrieved: 2026-09-17. This is the acquisition date, not a medical review date.
Clinical information, images and comparisons appear only when separately reviewed for this record. Coverage may be incomplete. Ask a pharmacist or clinician about your treatment.
Browse United States records →